September 2023 – Cantex Pharmaceuticals and Michigan Medicine announced the initiation of a randomized, double-blind, placebo-controlled, multicenter, Phase 3 pivotal clinical trial to evaluate the safety and efficacy of Cantex’s azeliragon in decreasing the incidence of acute kidney injury and other life-threatening complications in patients hospitalized for COVID-19.
September 2023 – Cantex Pharmaceuticals and Allegheny Health Network (AHN) announced the initiation of a Phase 1/2 study to assess the safety and efficacy of azeliragon in patients refractory to first-line treatment of metastatic pancreatic cancer.
September 2023 – Cantex Pharmaceuticals and Lenox Hill Hospital’s Department of Neurological Surgery announced the initiation of a Phase 2 study to assess the safety and effectiveness of azeliragon in combination with radiation therapy as a treatment for newly diagnosed unmethylated glioblastoma.
READ ALL NEWS